Spring Mountain Capital β Full Portfolio
9 tracked investments Β· listed companies and verified rows first
Allyx Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve and protect synapses in people with neurodegenerative diseases.
BiotechDigital HealthHealthtechNew Haven, US
Paul Fonteyne(Co-Founder)Stephen Strittmatter(Scientific Founder)Stephen Bloch(CEO, Co-Founder)Timothy Siegert(COO, Co-Founder)Jennifer Gabler(Executive Officer)
BoardRobert A. Bettigole(Director)in
Co-investorsElm Street VenturesConnecticut InnovationsWHIN
A Nashville-based company providing maternal healthcare services for pregnant mothers with opioid addiction, with a focus on behavioral health and postpartum contraceptive services.
HealthtechBrentwood, US
Justin Lanning(Executive Officer, Promoter)Bradley Towle(Executive Officer, Promoter)
BoardJamie Weston(Executive Officer, Director)Landon Gibbs(Executive Officer, Promoter)in
Genomenon uses AI to read biomedical literature and expert scientists to curate variant- and patient-level genomic evidence, delivering regulatory-grade real-world evidence.
AI & Machine LearningBiotechDigital HealthAnn Arbor, US
Mark Kiel(Executive Officer, Director)Eli Salembier(Executive Officer, Director)Sam Globus(Executive Officer)inDr. Sam Globus(Chief Operating Officer)Michael Klein(Executive Officer, Director)David Gregorka(Director)
Co-investorsBeringeaGreen Park & Golf VenturesID VenturesInvest MichiganIrishAngelsMarram Ventures+1 more
Hiveclass provides remote physical education and youth sports training instruction for kids.
EdTechFuture of WorkWellness & FitnessBridgehampton, US
Joe Titus(Founder)inPaul Suhr(Founder)in
Co-investorsSamvid VenturesTechstarsRethink Capital PartnersRethink Education
Prevalent, a Mitratech product, is an AI-powered third-party risk management (TPRM) platform for assessing, monitoring, and remediating risks across the vendor and supplier lifecycle from onboarding to offboarding.
AI & Machine LearningCybersecurityEnterprise SoftwareSaaSPhoenix, US
Norman W. Menz III(Director)Jonathan Dambrot(Director)Jonathan E. Dambrot(Executive Officer, Director)Norman W. Menz, III(Executive Officer, Director)Kevin Hickey(Chief Executive Officer)James Ray(Vice President of Finance, Corporate Secretary and Treasurer)
Co-investorsFulcrum Equity PartnersTappan Hill Ventures
Empowering enterprises and governments to reveal cyber risk and quickly orchestrate remediation
Sunnyvale, US
Dr. Srinivas Mukkamala(Executive Officer, Director)Brett Newsome(Executive Officer)
BoardWilliam Dennis Peterson(Director)Mourad Yesayan(Director)inJohn Stewart(Director)Greg Oslan(Director)
Co-investorsEPIC VENTURESPaladin Capital GroupJump CapitalSun Mountain Capital
New York, US
Edward Kim(Executive Officer, Director)Kent Krekorian(Executive Officer)Hal Muchnick(Executive Officer, Director)
BoardBo Peabody(Director)Benjamin Sun(Director)Kirk Wolfe(Director)
Co-investorsMI VenturesSocial StartsAtlas VentureMK Capital
Vergent develops tumor-targeted fluorescent imaging agents designed to enhance surgeons' ability to visualize tumors during minimally invasive and robotic-assisted cancer surgery.
BiotechDeep TechHealthtechMedical DevicesMinneapolis, US
Jeffrey Yurecko(Executive Officer)John Santini(Executive Officer, Director)John Santini, PhD(President and Chief Executive Officer)
BoardJeff Julkowski(Director)Raymond Wong(Director)Anita Watkins(Director)
Co-investorsColle Capital PartnersWindham Capital Partners
Yunu offers a clinical trial imaging platform that harmonizes imaging workflows, data, and compliance from initial scan through trial submission, cutting turnaround times and reducing manual work.
AI & Machine LearningBiotechHealthtechMedical DevicesSaaS
Jeffrey Sorenson(Chief Executive Officer)Gael Kuhn(Chief Technology Officer)Dr. Gordon Harris(Chief Science Officer)Lindsay Fleming(Chief Marketing Officer)Patrick McNamara(Chief Commercial Officer)in
Co-investorsFirst Analysis
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.